This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

It's Pipeline That Matters Most

This article originally appeared on May 1, 2013 on Real Money. To read more content like this + see inside Jim Cramer's multi-million dollar portfolio for FREE. Click Here NOW.

No matter how many times I say it, people don't seem to get it.

The pharmaceutical business is not about near-term earnings estimates or earnings just reported, it's all about pipeline, what's in the works, what could be blockbuster.

We are seeing all of that play out in today's trading. First, Merck (MRK) reports a quarter that is widely panned and people decide that Merck's "had it." But Merck has 35 drugs in the pipe and many of these could add very much in the out years. That's why Merck's committed to buying $15 billion of its stock now, because management knows that it has some huge drugs that will be terrific in the future. So why not try buying back $15 billion dollars in stock, or 10% of the company in the interim? Why not give people a 3.75% yield to wait for the Phase II and Phase III drugs that will be powering the numbers when 10% of the company was bought in cheap.

But then there's Allergan (AGN) today. I had high hopes for its macular degeneration drug because Allergan has such a fabulous ophthalmological pipeline. But the drug's being delayed because right now the drug's results aren't up to snuff. So, the stock falls about 10%t. Meanwhile, this great news for Regeneron, which has the best current drug out there for macular degeneration and the competitive woes from a much more establishes company just vanished. That gives Regeneron more money to develop its pipeline, assuring you more growth in the future. It doesn't hurt, by the way, that Regeneron's stock was heavily shorted because it went into the S&P 500 last night, causing a spike that wiseguys thought would be given up today. Whoops, the pipeline of Allergan wrecked that trade.

We've had some tremendous earnings disappointments from high-profile drug companies that simply ended up meaning nothing. Consider Lilly (LLY). It didn't hit the number, but it sure held out hope for a valid drug to treat Alzheimer's. We didn't hear anything blowout about the pipelines of Pfizer (PFE) and Bristol-Myers (BMY), so those legitimately sold off. But Pfizer is committed to bringing out value in other ways, including splitting the company up, so the pipeline isn't as important as others. But Bristol seems to have a gap, so that stock's not bouncing.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs